期刊文献+

人类免疫缺陷病毒I型Tat真核表达载体的构建及鉴定

Construction and in Vitro Expression of an Eukaryotic Vector Encoding HIV-1 Tat
原文传递
导出
摘要 目的构建人类免疫缺陷病毒Tat基因真核表达质粒,并研究该质粒在真核细胞中的有效表达。方法以含有HIV-1全长基因的质粒pNL4-3为模板,通过PCR扩增HIV-1 Tat第一外显子,应用基因工程技术将扩增的基因片段插入真核表达质粒pcDNA3.1(+),构建重组真核表达质粒pcDNA3.1-tat,经限制性内切酶酶切分析及测序鉴定正确后,应用脂质体转染技术转染入huh-7细胞。RT-PCR检测其基因转录情况,Western Blot鉴定其是否能够表达相应的目的蛋白质。结果成功扩增了Tat基因,酶切和测序证明正确构建了重组真核表达质粒pcDNA3.1-tat,RT-PCR和Western blot方法证实该质粒能在huh-7真核细胞中有效表达HIV-1 Tat目的蛋白质。结论成功构建了HIV-1 Tat基因的真核表达质粒载体,并在huh-7中表达,为在huh-7细胞模型中研究Tat的功能奠定了基础。 Objective To construct an eukaryotic plasmid expressing HIV-1 Tat and test whether the plasmid can be expressed in the eukaryotic cell in vitro.Methods The first exon of HIV-1 Tat was amplified by PCR from the plasmid pNL4-3.Then the Tat gene was inserted into the eukaryotic expression plasmid pCDNA3.1(+),and the resultant recombinant plasmid was confirmed by restriction endonuclease and sequencing,then was designated as pCDNA3.1-tat.The recombinant plasmid pCDNA3.1-tat was transfected into eukaryotic cell huh-7 by lipo-fectamine.RT-PCR and Western blot were used to certify whether the purpose protein was correctly expressed in huh-7 cells. Results The 240 bp DNA fragment of tat was correctly amplified.The recombinant pCDNA3.1-tat was successfully constructed,and it could be correctly expressed in the huh-7 cells. Conclusions This recombinant plasmid pCDNA3.1-tat and the resulting huh-7 cell model provide a basis for further study on the function of HIV-1 Tat.
作者 刘昭国
出处 《实用预防医学》 CAS 2010年第10期1961-1964,共4页 Practical Preventive Medicine
关键词 HIV-1Tat 载体构建 HUH-7细胞 表达 HIV-1 Tat Vector construction huh-7 cell Expression
  • 相关文献

参考文献14

  • 1Jeang KT, Xiao H, Rich EA. Multifaceted activities of the HIV 1 transactivator of transcription, Tat [J]. JB iol Chem, (Review).
  • 2Dandekar DH, Ganesh KN, Mitra D. HIV21 Tat directly binds to NFkappaB enhancer sequence: role in viral and cellular gene expression [J].. Nucleic Acids Res, 2004, 32(4) :1270- 1278.
  • 3崔凡,刘维达.HIV-1转录调控机制的研究进展[J].国外医学(皮肤性病学分册),2003,29(2):123-126. 被引量:8
  • 4Brigati C, Giacca M, Noonan DM, et al. HIV Tat, its TARgets and the control of viral gene expression[J]. FEMS Microbiol Lett, 2003, 220(1):57 -65.
  • 5Rusnati M, Tulipano G, Urbinati C, et al. The basic domain in HIV- 1 Tat protein as a target for polysulfonated heparin - mimicking extra cellular Tat antagonists[J]. J Biol Chem, 1998, 273 (26) : 16027-16037.
  • 6Ziegler A, Seelig J. Interaction of the protein transduction domain of HIV 1 TAT with heparan sulfate: binding mechanism and thermodynamic parameters[J]. Biophys J, 2004, 86(1Pt1) :254 - 263.
  • 7Verucchi G, Calza L, Redi RM, et al. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management [ J]. Infection, 2004,32 ( 1 ) : 3 - 46.
  • 8Monga HK, Rodriguez - Barradas MC, Breaux K, et al. Hepatitis C virus infection related morbidity and mortality among patients with human immunodeflciency virus infection [J]. Infect Dis, 2001,33 : 240 - 247.
  • 9RusnatiM, Tulipano G, Urbinati C, et al. The basic domain in HIV 1 Tat protein as a target for polysulfonated heparin mimicking extra cellular Tat antagonists [ J ]. J Biol Chem, 1998, 273 (26) : 16027 - 16037.
  • 10Rubartelli A, Poggi A, Sitia R, et al. HIV- 1 Tat: a polypeptide for all seasons[J]. Immunol Today, 1999, 20(8) :384 -385.

二级参考文献27

  • 1Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus:a cross-sectional analysis of the US adult AIDS clinical trials group. Clin Infec Dis,2002,34:831-837.
  • 2Zhang L, Cao Y, Yu J, et al. Outbreak of HIV- 1 and HCV infection among illegal blood donors in Henan province, China, Washington State Convention and Trade Center, Seattle, WA,2002.24-28.
  • 3Dragon F, CafoUa A, Giuseppe G, et al. HIV-HCV RNA loads and liver failure in coinfected patients with coagulopathy. Haematologica,1999,84 : 525-529.
  • 4Sulkowski MS, Mast EE, Seeff LB, et al. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infec Dis, 2000,30 ( suppl 1 ) : s77- s84.
  • 5Greene WC, Peterlin BM. Charting HIV;s remarkable voyage throughthe cell: Basic science as a passport to future therapy. Nat Med. 2002, 8(7) :673 -680.
  • 6Majello B, Napo1litano G, De Luca P, et al. Recruitment of human TBP selectively activates RNA polymerase Ⅱ TATA-dependent promoters. J Biol Chem. 1998, 273(26) :16509 -16516.
  • 7Zenzie-Gregory B, Sheridan P, Jones KA, etal. HIV - 1 core promoter lacks a simple initiator element but contains a bipartite activator at the transcription start site. J Biol Chem, 1993, 268 (21): 15823- 15832.
  • 8Sune C, Garcia-Blanco MA. Spl transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat. J Virol. 1995,69(10) :6572 - 6576.
  • 9Kretzschmar M, Meisterernst M, Scheidereit C, et al. Transcriptional regulation of the HIV - 1 promoter by NF-kappa B in vitro. Genes Dev, 1992, 6(5) :761 -774.
  • 10Takada N, Sanda T, Okamoto H, et al. RelA-associated inhibitor blocks transcription of human immunodeficiency virus type 1 by inhibiting NF-kappaB and Sp1 actions. J Virol, 2002, 76 ( 16 ): 8019 - 8030.

共引文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部